Drug Discovery Archives – DHbriefs

Dark Blue Therapeutics

Dusan Belic — Tue, 13 Jun 2023 05:13:17 +0000

Dark Blue Therapeutics is an innovative drug discovery biotechnology company leveraging ground-breaking cancer biology insights from Oxford University to discover and develop innovative precision medicines that exploit novel vulnerabilities and dependencies. With this deep, proprietary understanding of target biology, Dark Blue Therapeutics matches its precision medicines to molecularly defined patient populations to develop transformative, durable drugs that address critical unmet patient needs — delivering medicines that transform the outcomes for cancer patients. It works across various biological mechanisms to identify and pursue only cancer targets with the highest transformative potential.

The post Dark Blue Therapeutics appeared first on DHbriefs.

Qubit Pharmaceuticals

Dusan Belic — Sat, 03 Jun 2023 08:25:17 +0000

Qubit Pharmaceuticals aims to speed up the lengthy and costly drug discovery process, where potential drugs are screened from a very large number of molecules. It increases the accuracy of these calculations by leveraging the power of its own 200 GPU supercomputer, called Gaia, developed in partnership with Nvidia. Qubit’s software, called Atlas, has been demonstrated to have significantly higher accuracy than other approaches with multiple candidates in its pipeline in oncology. In addition to its Paris headquarters, the company has an office in Boston.

The post Qubit Pharmaceuticals appeared first on DHbriefs.

Pear Bio

Dusan Belic — Tue, 16 May 2023 19:38:41 +0000

Pear Bio is a computational biology company that uses organ-on-a-chip and computer vision technology to recreate, visualize and compute the human tumor microenvironment and its effects on cancer progression. The company is building an atlas of cancer progression to help research hospitals/pharma test experimental drugs and to help clinicians evaluate potential treatment options for each patient to improve outcomes. Pear Bio’s technology is applicable across solid tumors, and it is currently working on a pipeline of biomarker-negative cancers, with triple-negative breast cancer as the lead indication.

The post Pear Bio appeared first on DHbriefs.

Tailor Bio

Dusan Belic — Sat, 15 Apr 2023 14:35:36 +0000

With its AI-driven drug discovery platform, Tailor Bio is bringing precision medicine to the deadliest cancers. It provides clinical decision support to physicians, allowing them to select the best therapy for their patients’ treatments. To do this, Tailor Bio’s technology decodes chromosomal instability — a genomic phenomenon present in 80% of all cancers — and uses mutational signatures as biomarkers to inform therapy selection decisions.

The post Tailor Bio appeared first on DHbriefs.

Kuano

Dusan Belic — Tue, 28 Mar 2023 11:54:51 +0000

Kuano combines quantum physics, AI and medicinal chemistry in an approach to transforming the discovery of therapeutics focused on enzyme inhibition. Enzymes represent the largest class of drug targets, with over $40 billion of pharmaceutical sales attributable to small molecule inhibitors of enzymes. The market is seeing considerable demand for enzyme inhibitors, which can provide improved drug potency, selectivity or reduced susceptibility to resistance. Kuano is meeting this need through its novel, proprietary software platform for rapid, cost effective quantum modelling of enzymes. The company uses these models in combination with AI and chemistry approaches to design optimised inhibitors with improved properties for use in medicines.

The post Kuano appeared first on DHbriefs.

AgomAb Therapeutics

Dusan Belic — Thu, 29 Sep 2022 08:38:36 +0000

Founded through a collaboration between argenx and the University of Torino, Italy – Agomab is translating deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, it is building a broad clinical pipeline of differentiated programs with disease-modifying potential in organ failure and fibrotic diseases.

The post AgomAb Therapeutics appeared first on DHbriefs.

ELEM Biotech

Dusan Belic — Tue, 29 Mar 2022 13:36:59 +0000

ELEM Biotech is developing a Virtual Human technology that it hopes to become the standard for medical testing and in-silico clinical trials. More specifically, the company is creating cutting-edge supercomputer-based patient modeling and simulation solutions, deployed in the cloud, that help MedTech and Pharma companies, and CROs optimize their products and offer new evidence to clinicians to personalize treatments. At the moment, the company offers virtual cardiovascular and respiratory systems, with the idea to virtualize a completely interconnected network of organs and systems. ELEM is a spin-off from the Barcelona Supercomputing Center.

The post ELEM Biotech appeared first on DHbriefs.

CancerAppy

Dusan Belic — Fri, 18 Mar 2022 11:34:30 +0000

CancerAppy has developed a platform based on Big Data and AI, specialized in the field of cancer research, developed by and for scientists and drug developers that fills the gap between basic data tools and pharma intelligence tools. Said platform is meant to efficiently and effectively de-risk the process of cancer drug discovery and development and shorten the time-to-market of novel cancer drugs. It comprises of DrugOptimization to identify and validate novel targets and/or identify the mechanism of action of a compound, DrugCombination to explore potential drug combinations providing a score for the mixed drugs, and GeneReport, which is a personalized treatment matched application that permits score predicted treatments with patient genomic actionable information.

The post CancerAppy appeared first on DHbriefs.